Abstract
Inflammatory bowel disease (IBD) is a group of disorders characterized by chronic inflammation within the gastrointestinal tract. It is a multifactorial disease associated with immune-cell mediated oxidative damage to the intestinal mucosa. There is no cure for IBD, but anti-cytokine therapy can limit target inflammation and disease progression. Unfortunately, many patients are nonresponsive or develop resistance to anti-cytokine therapy over time creating a need for new therapeutic agents. Metallothionein (MT) is a small, highly conserved stress response protein that has been shown to modulate the immune response as a pro-inflammatory agent, regulates divalent heavy metal homeostasis, and acts as a reactive metabolite scavenger. Our research, as well as other groups studying MT, has described MT induction and release during IBD inflammatory stress response. The release of MT results in activation of inflammatory responses leading to progressive inflammation and subsequent expansion of MT synthesis. A monoclonal antibody specific for MT has been used in murine models of IBD and should only target the extracellular pool of MT, thus representing a novel therapeutic approach to this disease.
Keywords: Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Metallothionein, biologic therapy, inflammation.
Current Pharmaceutical Design
Title:Metallothionein: A Novel Therapeutic Target for Treatment of Inflammatory Bowel Disease
Volume: 24 Issue: 27
Author(s): Kristen E. Dostie, Amy V. Thees and Michael A. Lynes*
Affiliation:
- Department of Molecular and Cell Biology, University of Connecticut, Storrs,United States
Keywords: Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Metallothionein, biologic therapy, inflammation.
Abstract: Inflammatory bowel disease (IBD) is a group of disorders characterized by chronic inflammation within the gastrointestinal tract. It is a multifactorial disease associated with immune-cell mediated oxidative damage to the intestinal mucosa. There is no cure for IBD, but anti-cytokine therapy can limit target inflammation and disease progression. Unfortunately, many patients are nonresponsive or develop resistance to anti-cytokine therapy over time creating a need for new therapeutic agents. Metallothionein (MT) is a small, highly conserved stress response protein that has been shown to modulate the immune response as a pro-inflammatory agent, regulates divalent heavy metal homeostasis, and acts as a reactive metabolite scavenger. Our research, as well as other groups studying MT, has described MT induction and release during IBD inflammatory stress response. The release of MT results in activation of inflammatory responses leading to progressive inflammation and subsequent expansion of MT synthesis. A monoclonal antibody specific for MT has been used in murine models of IBD and should only target the extracellular pool of MT, thus representing a novel therapeutic approach to this disease.
Export Options
About this article
Cite this article as:
Dostie E. Kristen , Thees V. Amy and Lynes A. Michael *, Metallothionein: A Novel Therapeutic Target for Treatment of Inflammatory Bowel Disease, Current Pharmaceutical Design 2018; 24 (27) . https://dx.doi.org/10.2174/1381612824666180717110236
DOI https://dx.doi.org/10.2174/1381612824666180717110236 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Determination of Body Mass Index and Physical Activity in Normal Weight Children and Evaluation of Salivary Levels of Interleukin 10 and Interleukin 17
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Proteomic Analysis of Liver Preservation Solutions Prior to Liver Transplantation
Current Proteomics Insulin Secretagogues, Sulfonylurea Receptors and KATP Channels
Current Pharmaceutical Design Ovalbumin Induced Allergic Rhinitis and Development of Prediabetes to Rats: Possible Role of Th2 Cytokines
Inflammation & Allergy - Drug Targets (Discontinued) Animal Models of Lupus and Lupus Nephritis
Current Pharmaceutical Design Polypharmacy in Cardiovascular Medicine: Problems and Promises!
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Nitro (NO<sub>2</sub>-), Chloro (Cl), and Fluoro (F) Substitution in the Design of Antileishmanial and Antichagasic Compounds
Current Drug Targets Molecular Determinants of Vascular Calcification: A Bench to Bedside View
Current Molecular Medicine Is Galanin a Promising Therapeutic Resource for Neural and Nonneural Diseases?
Current Drug Targets Genomes to Hits In Silico - A Country Path Today, A Highway Tomorrow: A Case Study of Chikungunya
Current Pharmaceutical Design Chemokine Expression and Regulation of Angiogenesis in Rheumatoid Arthritis
Current Pharmaceutical Design Induction of a Robust Humoral Response using HIV-1 VLP<sup>MPER-V3</sup> as a Novel Candidate Vaccine in BALB/c Mice
Current HIV Research Immune Response to Helper Dependent Adenoviral Mediated Liver Gene Therapy: Challenges and Prospects
Current Gene Therapy Molecular Targets to Promote Central Nervous System Regeneration
Current Neurovascular Research Probiotics in the Mechanism of Protection Against Gut Inflammation and Therapy of Gastrointestinal Disorders
Current Pharmaceutical Design Targeting the Nogo Receptor Complex in Diseases of the Central Nervous System
Current Medicinal Chemistry TRPV1 and TRPA1 in Pulmonary Vagal Afferents and their Relations to Airway Sensitivity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia
Current Drug Targets Natriuretic Peptide Family: New Aspects
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Recent Progresses on The Improved Therapy of Melanoma by Novel Drug Delivery Systems
Current Drug Targets